The Entity of Hemorrhagic Necrosis of the Intestine

LeVine, Michael A.
November 1970
American Journal of Gastroenterology;Nov1970, Vol. 54 Issue 5, p490
Academic Journal
Hemorrhagic mucosal necrosis is briefly reviewed with reference to pathogenesis, microscopic and gross pathologic findings, clinical presentation and presently available therapy.


Related Articles

  • Treating the Dental Patient on Bisphosphonate Therapy. Goldberg, Michael; Tenenbaum, Howard C.; Grad, Helen // Ontario Dentist;Sep2007, Vol. 84 Issue 7, p40 

    The article presents an overview of the relevant information on bisphosphonate therapy and how it might affect the clinical practice of dentistry. Bisphosphonates are pyrophosphate analogues that were first recognized in the mid-nineteenth century and first prescribed therapeutically in the...

  • Alendronic acid.  // Reactions Weekly;9/1/2007, Issue 1167, p6 

    The article presents a case study of a 66-year old woman who has developed osteonecrosis of the jaw while receiving alendronic acid. She had been diagnosed with borderline osteoporosis and started taking alendronic acid 70mg weekly which lessened the pain. She had undergone dental reconstruction...

  • Novel agents for anti-platelet therapy.  // Journal of Hematology & Oncology;2011, Vol. 4 Issue 1, p44 

    The article presents a study focusing on novel agents for anti-platelet therapy. The study shows that the combined use of anti-platelet drugs with different mechanisms is significant in anti-thrombotic treatments. It also showed that further research on platelet functions may give rise to...

  • A2B Receptor Ligands: Past, Present and Future Trends. Ortore, G.; Martinelli, A. // Current Topics in Medicinal Chemistry;Jun2010, Vol. 10 Issue 9, p923 

    A2B adenosine receptors have been investigated in recent years as potential target for the treatment of different pathologies. The involvement of this receptor in processes such as interleukins secretion, Ca2+ mobilization, hepatic glucose regulation, tumor vascularisation, and cardioprotection...

  • Gout in 2006. Terkeltaub, Robert // Bulletin of the NYU Hospital for Joint Diseases;2006, Vol. 64 Issue 1/2, p82 

    Mechanistic and therapeutic advances in gout have been moving swiftly in the past decade. Clinically, the disease is changing in character. This review discusses several of the pertinent recent developments in understanding gout and in novel therapeutics for the disease. Subjects addressed...

  • Seborrheic keratosis. Thompson, Lester D. R. // ENT: Ear, Nose & Throat Journal;Feb2006, Vol. 85 Issue 2, p79 

    Examines the pathology of seborrheic keratosis. Symptoms of seborrheic keratosis; Treatments for the disease.

  • Network target for screening synergistic drug combinations with application to traditional Chinese medicine. Shao Li; Bo Zhang; Ningbo Zhang // BMC Systems Biology;Jan2011 Supplement 1, Vol. 5, p1 

    Background: Multicomponent therapeutics offer bright prospects for the control of complex diseases in a synergistic manner. However, finding ways to screen the synergistic combinations from numerous pharmacological agents is still an ongoing challenge. Results: In this work, we proposed for the...

  • Minimally Invasive Therapy for Benign Tumors of the Distal Third of the Esophagus—A Single Institute's Experience. Palanivelu, Chinnusamy; Rangarajan, Muthukumaran; Madankumar, Madhupalayam Velusamy; John, Suviraj J.; Senthilkumar, Rangasamy // Journal of Laparoendoscopic & Advanced Surgical Techniques;Feb2008, Vol. 18 Issue 1, p20 

    Introduction: Traditionally, the treatment of benign esophageal tumors is enucleation achieved via a thoracotomy. Since 1992, many reports of thoracoscopic and laparoscopic approaches have been published. In this paper, we present a retrospective study of 18 patients with benign distal...

  • Gangrene complicating dopamine therapy. Kaul, S.; Sarela, A. I.; Supe, A. N.; Karnard, D. R. // Journal of the Royal Society of Medicine;Feb1997, Vol. 90 Issue 2, p80 

    The article presents the clinical case of a forty-year-old man exhibiting gangrene as a complication of low-dose dopamine therapy for the management of septic and cardiogenic shock. The gangrene suggests a multifactorial cause of the necrosis and ischemia or an idiosyncratic response to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics